Precision Epigenomics

04/19/2026

This week, we recognize our brilliant Medical Laboratory Professionals! Your dedication fuels our innovation. Thank you to the scientists and doctors at Precision Epigenomics for their hard work in making multi-cancer early detection a reality.

04/16/2026

Age 45 is a major milestone—not just for your life, but for your health.

By 45, your "Screening To-Do List" grows: ✔️ Yearly Mammograms (started at 40) ✔️ Colorectal Screening (starts at 45) ✔️ Prostate Screening (starts at 45-50)

Standard screenings are the gold standard, but they only look for a handful of cancers. For more extensive protection, add EPISEEK to your routine. One blood draw screens for 60+ types of cancer, catching what traditional tests might miss.

Don't leave your health to chance. Enhance your routine screening with MCED technology.

HSA/FSA eligible

04/12/2026

Take control of your health with proactive screening. The EPISEEK-MCED liquid biopsy test is an accessible tool for early cancer detection, specifically recommended for adults aged 45 and older.
Younger than 45 but have elevated risk factors? You may benefit, too! Talk to your doctor today.

04/10/2026

Catching cancer at Stage I or II significantly improves outcomes. This April, for Early Cancer Detection Month, now is the time to take action.

With the EPISEEK® blood test, screening is more reliable, accessible, and affordable than ever. See if you qualify today.

EPISEEK is HSA/FSA eligible

04/10/2026

Know Your Risk Factors for Esophageal Cancer!

GERD, Barrett's Esophagus, obesity, to***co, and heavy alcohol use significantly increase your risk.
Don't wait for symptoms. EPISEEK-MCED allows you to proactively screen for esophageal cancer and over 60 other cancers. Know your risk. Get screened.

04/07/2026

We’re excited to share that Precision Epigenomics has been featured in an article by AZBio!

It’s an honor to be recognized for our commitment to advancing affordable, early cancer detection through our innovative EPISEEK liquid biopsy test. We’re grateful for the opportunity to share our mission: to change the way cancer is detected, managed, and ultimately survived.

Thank you to AZBio for highlighting our company!

Precision Epigenomics focuses on addressing cancer by targeting epigenetic changes (i.e., DNA methylation) that drive tumor development, progression, and treatment resistance. While genetic mutations have long been a focus in oncology, epigenetic dysregulation plays a critical role in how cancer cel...

04/07/2026

Celebrating World Health Day! We honor the global effort to advance public health.

Precision Epigenomics is doing its part by making highly accurate, multi-cancer early detection accessible worldwide. Better health starts with better screening!

04/06/2026

Happy National Public Health Week! This week, we celebrate the tireless commitment to disease prevention and protecting our communities.

At Precision Epigenomics, our public health commitment is rooted in health equity. We are dedicated to transforming wellness by offering affordable and reliable cancer screening with the EPISEEK test, ensuring cutting-edge detection is accessible to all.

04/03/2026

Testicular cancer is highly curable—but early detection is so important!

Manage your risk (family history, cryptorchidism, etc.) proactively with EPISEEK-MCED. Take control of your health today!

04/01/2026

The Future of Screening is Here!
This April, take control of your health. Precision Epigenomics is committed to transforming healthcare with cutting-edge technology that identifies multiple cancer types at their earliest stages through a simple liquid biopsy.

Early detection = Better outcomes.

03/30/2026

Happy National Doctors Day! To every physician dedicating countless hours to patient well-being: thank you.

We share your goal of finding cancer as early as possible. EPISEEK MCED is a powerful tool to help you proactively screen for over 60 cancers, supporting your commitment to excellence in care.

03/25/2026

Check out the letter Rich Bernert sent to the editor in this month’s CAP Today, bringing awareness of the promise of liquid biopsy in cancer detection and the Nancy Gardner Sewell Act.

https://www.captodaymag.com/captoday/library/page/march_2026/12/

The training ofpathologists’ assistants I wholeheartedly agree with ArthurMensch, MD, about the need for morepathologist involvement in supervising gross examinations of resectionspecimens (Letters...